Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis
Status:
Completed
Trial end date:
2021-04-21
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the safety and efficacy of administering 372.6
mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients
with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events
after starting the study treatment).